Lanean...
The BRAF(V600E) mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy?
OBJECTIVES: Preclinical studies showed that BRAF(V600E) mutation significantly reduced radioiodine uptake and decreased the sensitivity to radioactive iodine (RAI) therapy. However, clinical data regarding its role in therapeutic decision making with respect to RAI therapy are currently insufficient...
Gorde:
| Argitaratua izan da: | Nucl Med Commun |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Lippincott Williams & Wilkins
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6282664/ https://ncbi.nlm.nih.gov/pubmed/30312216 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MNM.0000000000000930 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|